RSPH vs XLV

Key Takeaways

• RSPH tracks an equal-weighted index of S&P 500 health care stocks, resulting in broader diversification across approximately 60 holdings with no single position exceeding roughly 2-3% of assets.
• XLV follows a market-capitalization-weighted index of the same S&P 500 health care universe, concentrating exposure in mega-cap names such as Eli Lilly and Johnson & Johnson, which can account for over 25% of the fund combined.
• RSPH carries an expense ratio of 0.40%, while XLV offers a significantly lower expense ratio of 0.08%, enhancing long-term cost efficiency for investors.
• Both ETFs provide pure-play exposure to the U.S. health care sector with 100% allocation to the industry, but RSPH introduces a modest tilt toward mid-cap companies through its equal-weight methodology.
• XLV benefits from substantially higher assets under management and trading volume, supporting tighter bid-ask spreads and greater liquidity for larger institutional positions.
• The equal-weight approach in RSPH reduces concentration risk relative to XLV but may lead to different performance outcomes during periods of strong mega-cap outperformance within health care.

Introduction

Investors seeking targeted exposure to the U.S. health care sector often evaluate RSPH and XLV as complementary or alternative vehicles. These ETFs do not compete directly as broad-market solutions but instead offer differentiated strategies within the same sector. RSPH emphasizes equal weighting to mitigate concentration, while XLV delivers conventional market-cap exposure to leading health care companies. The comparison helps investors align portfolio construction with preferences for diversification versus cost and liquidity in the current environment of evolving sector dynamics.

Invesco S&P 500 Equal Weight Health Care ETF (RSPH) Overview

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a passively managed fund that seeks to track the S&P 500 Equal Weight Health Care Index. The index includes all S&P 500 companies classified under the health care sector according to the Global Industry Classification Standard (GICS) and applies equal weighting with quarterly rebalancing. RSPH typically holds 60 to 63 securities, with top holdings generally representing 2% or less of assets each. Key positions often include companies such as Moderna, Bio-Techne, and Charles River Laboratories. The fund maintains a 100% allocation to the health care sector and carries an expense ratio of 0.40%. Its equal-weight structure provides a structural tilt toward mid-cap names compared with cap-weighted peers.

Health Care Select Sector SPDR Fund (XLV) Overview

The Health Care Select Sector SPDR Fund (XLV) is a passively managed exchange-traded fund designed to track the Health Care Select Sector Index. This index comprises S&P 500 health care companies weighted by market capitalization and covers sub-industries including pharmaceuticals, biotechnology, health care equipment and supplies, and providers and services. XLV holds approximately 60 securities, with significant concentration in the largest constituents. Top holdings frequently include Eli Lilly, Johnson & Johnson, and AbbVie, which together can exceed 30% of assets. The fund maintains a 100% health care sector allocation and features a low expense ratio of 0.08%. It is sponsored by State Street and benefits from high liquidity due to its scale.

Industry and Thematic Backdrop

The U.S. health care sector encompasses pharmaceuticals, biotechnology, medical devices, and services providers, all subject to regulatory oversight, innovation cycles, and demographic tailwinds from an aging population. Capital flows into the sector are influenced by drug pipeline developments, patent expirations, and policy changes around pricing and reimbursement. Macroeconomic factors such as interest rate expectations affect valuation multiples, while geopolitical events and supply chain considerations can impact equipment and services segments. Both ETFs reflect these broad drivers but respond differently based on their weighting methodologies during periods of sector rotation or earnings divergence among large and mid-sized companies.

Performance and Positioning Comparison

In recent market cycles, XLV has often benefited from strong performance in its largest holdings, particularly during periods when mega-cap pharmaceutical and biotechnology companies outperformed. RSPH’s equal-weight approach has provided more balanced exposure, potentially reducing volatility from any single name but leading to relative underperformance when mega-caps dominate. Over broader timeframes, the structural differences in diversification and cost have influenced relative returns, with XLV’s lower expense ratio supporting compounding advantages. Investors evaluating positioning consider how each fund aligns with expectations for continued innovation-driven growth versus broader participation across health care sub-sectors.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Professional and retail investors seeking data-driven insights into ETFs like RSPH and XLV may find the platform useful for refining their analysis.

Tickeron AI Verdict

Based on observable structural characteristics, Tickeron’s AI would likely assign a higher probability of favor to XLV in the current environment. The combination of a materially lower expense ratio, greater liquidity, and established positioning within the health care sector supports its relative appeal for cost-conscious investors prioritizing efficiency and scale. RSPH offers meaningful diversification benefits through equal weighting, which may appeal in scenarios emphasizing reduced concentration risk. The choice ultimately depends on an investor’s specific objectives regarding cost, liquidity, and portfolio construction preferences.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations